- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
NAGE
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Niagen Bioscience, Inc. · Healthcare · Biotechnology
Latest close
3.40 USD
5.9%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -23.3% below the Trend Line and sits at 3.5% of its 52-week range. The latest completed week returned 5.9%, after a -0.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: volume confirmation is below normal; earnings are due in 2d.
Setup score
21
out of 100
Latest Close
3.40 USD
31 Jul 2026
1W Return
5.9%
latest completed week
4W Return
-0.9%
short-term follow-through
12W Return
-18.5%
quarterly tape
Trend Breadth
15.4%
8 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.9%
Latest completed week; four-week move -0.9%.
Indicator stack
8/46
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.35%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
52/100 conviction; expected move 40.1%.
News sentiment
56/100
64 relevant articles in the latest sentiment read.
Event risk
2d
Next report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -23.3% below the Trend Line and sits at 3.5% of its 52-week range. The latest completed week returned 5.9%, after a -0.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0012-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.00Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -0.9% over four weeks, -18.5% over 12 weeks, and -62.4% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year8
Trend breadth15.4%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.24Latest activity-pressure read.
Pressure change8.6%Four-week change in activity pressure.
Leadership-48.60Latest relative-leadership reading.
RS change11.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 97%
Model confidence 93%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength61/100Blend of value, momentum, and quality. Underlying universe rank 40; rank 1 is best.
Value66/100Relative valuation strength. Underlying universe rank 35; rank 1 is best.
Quality83/100Profitability and accounting quality. Underlying universe rank 18; rank 1 is best.
Momentum3/100Medium-term price momentum. Underlying universe rank 98; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework88/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 13.7x Price divided by trailing earnings.
- Price / sales
- 2.0x Market value relative to trailing revenue.
- EV / EBITDA
- 9.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 2.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 64.3% Gross profit retained from each unit of revenue.
- Operating margin
- 15.1% Operating profit retained from revenue.
- Free-cash-flow margin
- 3.6% Free cash flow generated from revenue.
- Return on invested capital
- 101.5% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 20.8% Latest one-year revenue growth.
- EPS growth
- 32.1% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -76.1% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -1.6% Net share repurchases relative to market value.
- Shareholder yield
- -1.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -3.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
NAGE shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.03, expected move of 40.1%, and Sharemaestro trend signal inactive.
Conviction52/100
Expected move40.1%
Put/call volume0.03
Insider activity-
No recent insider transactions are stored for this company.
News sentiment56/100
Weighted news tone is neutral across 64 relevant articles.
17 positive · 44 neutral · 3 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
Options expected move40.1%Nearest-chain priced movement where available.
52-week drawdown-69.9%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher11 of 2614 weeks finished lower.
Best week+7.6%Week of 17 Apr.
Worst week-14.0%Week of 8 May.
Latest week+5.9%Week of 31 Jul.
Shape of recent returns
Strong gains4
Modest gains7
Flat weeks1
Modest losses7
Sharp losses7
Recent vol6.0%13-week weekly-return volatility.
Base vol6.3%52-week weekly-return volatility.
Up/down split22/28Count of positive and negative weeks in the 52-week window.
Average skew3.1% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape19/100
Trend, activity pressure, participation, and risk combine to a 19/100 tape read.
Indicator analysis21/100Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.
Activity pressure 0.00; No reversal markers Next-Week ExpectancyNegative 42.35%Next-week expectancy is negative with a 42.35% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 78; Small Cap Core rank 76 SVQF88/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 85.5 of 726 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100NAGE shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.03, expected move of 40.1%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 40.1% Sentiment56/100Weighted news tone is neutral across 64 relevant articles.
Arrowstreet Capital Limited Partnership Buys 761,685 Shares of Niagen Bioscience, Inc. $NAGE Insiders50/100No recent insider transaction evidence is stored.
Earnings2dNext report is scheduled for 04 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 3.40 USD | 5.9% | 4.43 USD | 5.01 USD | -0.24 | -48.60 | 3.0M | Off |
| 24 Jul 2026 | 3.21 USD | -2.1% | 4.53 USD | 5.00 USD | -0.25 | -52.30 | 3.3M | Off |
| 17 Jul 2026 | 3.28 USD | -3.2% | 4.64 USD | 4.99 USD | -0.11 | -53.12 | 4.3M | Off |
| 10 Jul 2026 | 3.39 USD | -1.2% | 4.75 USD | 4.98 USD | -0.14 | -54.73 | 3.5M | Off |
| 3 Jul 2026 | 3.43 USD | 0.3% | 4.86 USD | 4.97 USD | -0.27 | -54.70 | 2.3M | Off |
| 26 Jun 2026 | 3.42 USD | -2.3% | 4.96 USD | 4.95 USD | -0.38 | -55.89 | 4.7M | Off |
| 19 Jun 2026 | 3.50 USD | 1.4% | 5.07 USD | 4.94 USD | -0.34 | -58.43 | 2.6M | Off |
| 12 Jun 2026 | 3.45 USD | 0.0% | 5.18 USD | 4.93 USD | -0.33 | -59.37 | 2.9M | Off |
| 5 Jun 2026 | 3.45 USD | -10.6% | 5.29 USD | 4.92 USD | -0.21 | -59.82 | 3.8M | Off |
| 29 May 2026 | 3.86 USD | 5.5% | 5.41 USD | 4.91 USD | -0.03 | -58.36 | 5.1M | Off |
| 22 May 2026 | 3.66 USD | 0.3% | 5.53 USD | 4.89 USD | 0.09 | -60.33 | 3.9M | Off |
| 15 May 2026 | 3.65 USD | -12.5% | 5.66 USD | 4.88 USD | 0.30 | -60.80 | 6.6M | Off |
| 8 May 2026 | 4.17 USD | -14.0% | 5.78 USD | 4.86 USD | 0.32 | -56.38 | 6.9M | Off |
| 1 May 2026 | 4.85 USD | -1.6% | 5.89 USD | 4.85 USD | -0.06 | -47.41 | 3.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.